Welcome to our dedicated page for Lite Strategy SEC filings (Ticker: LITS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lite Strategy, Inc. filings document the company’s public-company transition, operating results, Litecoin treasury strategy, and capital-allocation actions. Form 8-K disclosures include furnished financial results, the board-authorized common stock repurchase program, and equity securities activity tied to pre-funded warrants issued in a private placement.
The filings also cover governance and compensation matters, including annual meeting voting results, director elections and resignation, executive appointment to chief executive officer and the board, stock option grants, and approval of the 2026 Omnibus Equity Compensation Plan. SEC reports identify MEI Pharma, Inc. as the company’s former name and support the current Lite Strategy identity.
Lite Strategy, Inc. announced that its Board has appointed Justin J. File as permanent Chief Executive Officer and elected him to the Board of Directors, effective immediately. He will continue to serve as Chief Financial Officer and Secretary, consolidating the company’s top executive and financial roles under a single leader.
In connection with his promotion, Mr. File received stock options to purchase 635,000 shares of common stock at an exercise price of $2.02 per share, which was the closing price on the grant date. These options were issued under the company’s Amended and Restated 2008 Stock Omnibus Equity Compensation Plan and vest in 36 monthly installments starting December 14, 2025, with a 10-year term. Mr. File will not receive additional compensation for serving on the Board, and the company plans to enter into an addendum to his employment agreement to document the new terms.
Lite Strategy, Inc. (Nasdaq: LITS) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $3.6 million, a narrower loss than the $8.0 million in the prior year period, as operating expenses declined with R&D falling to $10 thousand and G&A to $3.1 million. A $0.6 million loss from change in fair value of digital assets was recognized.
Balance sheet strength shifted to digital assets. Cash and cash equivalents were $10.1 million, and Litecoin holdings were $99.4 million, reflecting 929,548 LTC acquired under the new Litecoin Treasury Strategy following a $100.0 million July 2025 PIPE. Total assets were $113.3 million and stockholders’ equity was $112.3 million.
Capital actions and liquidity. In July, the company issued 23.2 million common shares at $3.42 and pre-funded warrants in the PIPE, and raised an additional $4.6 million net via its ATM. Operating cash use was $4.5 million; $100.0 million was deployed to purchase LTC; financing provided $96.6 million. Subsequent to quarter-end, remaining PIPE pre-funded warrants were exercised and the Board authorized a $25.0 million share repurchase program.
Lite Strategy, Inc. (LITS) filed an 8-K announcing two items. First, Thomas C. Reynolds, M.D., Ph.D. notified the Board on October 24, 2025 of his decision to resign as a director, effective November 4, 2025. He will also step down from the Compensation Committee and the Nominating & Governance Committee. The company stated his resignation is not the result of any disagreement with operations, policies, or practices.
Second, the Board authorized a common stock repurchase program under which the company may purchase up to $25 million of its common stock, as announced via press release on October 29, 2025. Repurchases may occur in the open market, through privately negotiated transactions, or under Rule 10b5-1 plans, subject to market conditions, applicable law, and other factors. The program does not obligate any repurchases and may be suspended or discontinued at any time.
MEI Pharma, Inc. filed a shelf registration on Form S-3 that describes the company's capitalization and resale mechanics for existing holders. The filing discloses $0.00000002 par value for each of up to 226,000,000 shares of common stock and 100,000 shares of undesignated preferred stock. As of June 30, 2025, 102,513 common shares are issuable upon exercise of warrants at $6.80 per share, 869,168 shares are issuable upon exercise of options with a weighted-average exercise price of $32.85, 920,737 shares are reserved under the 2008 Omnibus Plan, and 169,698 shares are reserved under the 2021 Inducement Plan. The filing lists a range of permitted sale methods for selling stockholders including brokerage, block trades, privately negotiated transactions, option/hedging arrangements, and other lawful methods. It also describes a three-year restriction on certain transfers by any stockholder who becomes an interested stockholder (owner of 15% or more voting stock) unless specific board approvals or exceptions apply. The filing cross-references the company’s Annual Report for the fiscal year ended June 30, 2025 and several Current Reports filed in July–September 2025.
Lite Strategy, Inc. (LITS) director Lee Charles Benjamin received a non‑derivative grant of 10,000 stock options on 10/03/2025 with an exercise price of $2.56. The option is a stock option exercisable into 10,000 shares of common stock and expires on 10/03/2035. The grant vests in 36 equal monthly installments, with the first monthly installment vesting one month after the grant, subject to continued service through each vesting date. Following the reported transaction the reporting person is shown as beneficially owning the 10,000 underlying shares on a direct basis. The filing was submitted under power of attorney by Justin J. File and dated 10/06/2025.
Flynn James P, a director of Lite Strategy, Inc. (ticker LITS), reported a purchase of 10,000 shares of the company's common stock on 09/30/2025. The filing shows a weighted-average purchase price of $2.543 per share, with individual transactions priced between $2.51 and $2.58. After the acquisition, Flynn beneficially owned 17,900 shares.
The Form 4 was submitted on 10/02/2025 and signed by an attorney-in-fact. The reporting person offers to provide details on the split of share counts by price within the disclosed range upon request.
Lite Strategy, Inc. (filing excerpts) discloses equity plan details, leadership changes, executive pay and severance terms, option activity, license and contingent payment obligations, and committee responsibilities. The company has omnibus and inducement equity plans authorizing 1,850,739 and 217,000 shares respectively, with specific option pools and weighted-average exercise prices reported. Leadership changes included resignations of the CEO and CMO effective August 1, 2024, with separation agreements providing severance, COBRA and accelerated vesting; one former CEO received $614,000 severance. Justin J. File became Acting CEO (in addition to CFO) and received total annual compensation of $912,667 and a $275,000 annual incentive plus a $96,000 success fee tied to cash retention. The filing notes cashless exercises and warrant conversions totaling millions of shares issued and lists committee charters and oversight duties for audit, compensation and nominating committees.
Lite Strategy, Inc. reported that an investor exercised a portion of previously issued pre-funded warrants. These warrants were originally issued on July 22, 2025 in a private PIPE offering at an offering price of $3.4199 per pre-funded warrant for up to 6,022,869 shares of common stock.
On September 10, 2025, the investor exercised 1,595,000 pre-funded warrants in a cashless transaction, receiving 1,594,944 shares of Lite Strategy common stock. The warrants and the shares issued upon exercise were issued in transactions relying on private offering exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.